Novel TGF-β antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation

Journal of Immunology

Volumn 186, Issue 12, 2011, Pages 6933-6944

  Penafuerte, Claudia ^a,b   Bautista Lopez, Norma ^b   Bouchentouf, Manaf ^a,b   Birman, Elena ^b   Forner, Kathy ^b   Galipeau, Jacques ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2 FUSION PROTEIN; SMAD7 PROTEIN; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOID CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; KILLER CELLS, NATURAL; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; STAT1 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN;

EID: 79959554877     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003816     Document Type: Article

References (60)

1. Reiss, M. 1999. TGF-beta and cancer. Microbes Infect. 1: 1327-1347.
2. Elliott, R. L., and G. C. Blobe. 2005. Role of transforming growth factor beta in human cancer. J. Clin. Oncol. 23: 2078-2093.
3. Muraoka, R. S., N. Dumont, C. A. Ritter, T. C. Dugger, D. M. Brantley, J. Chen, E. Easterly, L. R. Roebuck, S. Ryan, P. J. Gotwals, et al. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109: 1551-1559.
4. Peng, S. B., L. Yan, X. Xia, S. A. Watkins, H. B. Brooks, D. Beight, D. K. Herron, M. L. Jones, J. W. Lampe, W. T. McMillen, et al. 2005. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 44: 2293-2304. (Pubitemid 40279534)
5. Bandyopadhyay, A., J. K. Agyin, L. Wang, Y. Tang, X. Lei, B. M. Story, J. E. Cornell, B. H. Pollock, G. R. Mundy, and L. Z. Sun. 2006. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 66: 6714-6721.
6. Wick, W., U. Naumann, and M. Weller. 2006. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des. 12: 341-349.
7. Derynck, R., D. V. Goeddel, A. Ullrich, J. U. Gutterman, R. D. Williams, T. S. Bringman, and W. H. Berger. 1987. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 47: 707-712.
8. ten Dijke, P., K. Miyazono, and C. H. Heldin. 2000. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem. Sci. 25: 64-70.
9. Lagna, G., A. Hata, A. Hemmati-Brivanlou, and J. Massagué. 1996. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383: 832-836. (Pubitemid 26372668)
10. Feng, X. H., and R. Derynck. 2005. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21: 659-693.
11. Itoh, S., and P. ten Dijke. 2007. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr. Opin. Cell Biol. 19: 176-184.
12. Kavsak, P., R. K. Rasmussen, C. G. Causing, S. Bonni, H. Zhu, G. H. Thomsen, and J. L. Wrana. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6: 1365-1375.
13. Goumans, M. J., and C. Mummery. 2000. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol. 44: 253-265.
14. Dickson, M. C., J. S. Martin, F. M. Cousins, A. B. Kulkarni, S. Karlsson, and R. J. Akhurst. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121: 1845-1854.
15. Oshima, M., H. Oshima, and M. M. Taketo. 1996. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179: 297-302.
16. Goumans, M. J., G. Valdimarsdottir, S. Itoh, A. Rosendahl, P. Sideras, and P. ten Dijke. 2002. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21: 1743-1753.
17. Zhou, J., J. Zhang, M. G. Lichtenheld, and G. G. Meadows. 2002. A role for NF-kappa B activation in perforin expression of NK cells upon IL-2 receptor signaling. J. Immunol. 169: 1319-1325.
18. Yu, T. K., E. G. Caudell, C. Smid, and E. A. Grimm. 2000. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 164: 6244-6251.
19. Zhang, J., I. Scordi, M. J. Smyth, and M. G. Lichtenheld. 1999. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J. Exp. Med. 190: 1297-1308.
20. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105-2116.
21. Bright, J. J., L. D. Kerr, and S. Sriram. 1997. TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. J. Immunol. 159: 175-183. (Pubitemid 127493699)
22. Nelson, B. H., T. P. Martyak, L. J. Thompson, J. J. Moon, and T. Wang. 2003. Uncoupling of promitogenic and antiapoptotic functions of IL-2 by Smad-dependent TGF-beta signaling. J. Immunol. 170: 5563-5570. (Pubitemid 36617845)
23. Penafuerte, C., and J. Galipeau. 2008. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol. Immunother. 57: 1197-1206.
24. Dong, M., T. How, K. C. Kirkbride, K. J. Gordon, J. D. Lee, N. Hempel, P. Kelly, B. J. Moeller, J. R. Marks, and G. C. Blobe. 2007. The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Invest. 117: 206-217.
25. Wang, Z. G., W. Zhao, M. Ramachandra, and P. Seth. 2006. An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation. Mol. Cancer Ther. 5: 367-373.
26. Rowland-Goldsmith, M. A., H. Maruyama, T. Kusama, S. Ralli, and M. Korc. 2001. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin. Cancer Res. 7: 2931-2940.
27. Suzuki, E., V. Kapoor, H. K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda. 2004. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin. Cancer Res. 10: 5907-5918.
28. Yakymovych, I., U. Engström, S. Grimsby, C. H. Heldin, and S. Souchelnytskyi. 2002. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry 41: 11000-11007. (Pubitemid 35001214)
29. Bakin, A. V., A. K. Tomlinson, N. A. Bhowmick, H. L. Moses, and C. L. Arteaga. 2000. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275: 36803-36810.
30. Tzai, T. S., C. I. Lin, A. L. Shiau, and C. L. Wu. 1998. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res. 18(3A): 1585-1589.
31. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
32. Stagg, J., J. H. Wu, N. Bouganim, and J. Galipeau. 2004. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res. 64: 8795-8799. (Pubitemid 39665478)
33. Bouchentouf, M., P. Paradis, K. A. Forner, J. Cuerquis, M. N. Boivin, J. Zheng, M. R. Boulassel, J. P. Routy, E. L. Schiffrin, and J. Galipeau. 2010. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant. 19: 369-386.
34. Mosmann, T. R., T. Yokota, R. Kastelein, S. M. Zurawski, N. Arai, and Y. Takebe. 1987. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J. Immunol. 138: 1813-1816. (Pubitemid 17040806)
35. Saunders, B. M., and C. Cheers. 1996. Intranasal infection of beige mice with Mycobacterium avium complex: role of neutrophils and natural killer cells. Infect. Immun. 64: 4236-4241.
36. Gombert, J. M., A. Herbelin, E. Tancrède-Bohin, M. Dy, C. Carnaud, and J. F. Bach. 1996. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur. J. Immunol. 26: 2989-2998.
37. Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. B. DiCioccio, D. A. Gross, C. A. Mao, et al. 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043. (Pubitemid 37386196)
38. Lin, J. X., and W. J. Leonard. 2000. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19: 2566-2576.
39. Delespine-Carmagnat, M., G. Bouvier, and J. Bertoglio. 2000. Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain. Eur. J. Immunol. 30: 59-68.
40. Yu, C. R., H. A. Young, and J. R. Ortaldo. 1998. Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells. J. Leukoc. Biol. 64: 245-258.
41. Ulloa, L., J. Doody, and J. Massagué. 1999. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397: 710-713.
42. Zhang, S., T. Fei, L. Zhang, R. Zhang, F. Chen, Y. Ning, Y. Han, X. H. Feng, A. Meng, and Y. G. Chen. 2007. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol. Cell. Biol. 27: 4488-4499.
43. Yu, J., M. Wei, B. Becknell, R. Trotta, S. Liu, Z. Boyd, M. S. Jaung, B. W. Blaser, J. Sun, D. M. Benson, Jr., et al. 2006. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 24: 575-590. (Pubitemid 43728149)
44. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16: 137-161.
45. Horwitz, D. A., J. D. Gray, and K. Ohtsuka. 1999. Role of NK cells and TGF-beta in the regulation of T-cell-dependent antibody production in health and autoimmune disease. Microbes Infect. 1: 1305-1311. (Pubitemid 30020326)
46. Dennler, S., M. J. Goumans, and P. ten Dijke. 2002. Transforming growth factor beta signal transduction. J. Leukoc. Biol. 71: 731-740.
47. Gu, H., H. Maeda, J. J. Moon, J. D. Lord, M. Yoakim, B. H. Nelson, and B. G. Neel. 2000. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol. Cell. Biol. 20: 7109-7120.
48. Hand, T. W., W. Cui, Y. W. Jung, E. Sefik, N. S. Joshi, A. Chandele, Y. Liu, and S.M. Kaech. 2010. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl. Acad. Sci. USA 107: 16601-16606.
49. Stopa, M., D. Anhuf, L. Terstegen, P. Gatsios, A. M. Gressner, and S. Dooley. 2000. Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. J. Biol. Chem. 275: 29308-29317.
50. Sotomayor, M. G., H. Yu, S. Antonia, E. M. Sotomayor, and D. M. Pardoll. 2002. Advances in gene therapy for malignant melanoma. Cancer Contr. 9: 39-48.
51. Battle, T. E., R. A. Lynch, and D. A. Frank. 2006. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 66: 3649-3657.
52. Giese, N. A., Z. Raykov, L. DeMartino, A. Vecchi, S. Sozzani, C. Dinsart, J. J. Cornelis, and J. Rommelaere. 2002. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 9: 432-442. (Pubitemid 34438585)
53. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferoninducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182: 155-162.
54. Mikhak, Z., C. M. Fleming, B. D. Medoff, S. Y. Thomas, A. M. Tager, G. S. Campanella, and A. D. Luster. 2006. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. J. Immunol. 176: 4959-4967.
55. Wendel, M., I. E. Galani, E. Suri-Payer, and A. Cerwenka. 2008. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68: 8437-8445.
56. Bodnar, R. J., C. C. Yates, M. E. Rodgers, X. Du, and A. Wells. 2009. IP-10 induces dissociation of newly formed blood vessels. J. Cell Sci. 122: 2064-2077.
57. Grant, D. S., K. Tashiro, B. Segui-Real, Y. Yamada, G. R. Martin, and H. K. Kleinman. 1989. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58: 933-943.
58. Strieter, R. M., S. L. Kunkel, D. A. Arenberg, M. D. Burdick, and P. J. Polverini. 1995. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210: 51-57.
59. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182: 219-231.
60. Yang, Y. A., O. Dukhanina, B. Tang, M. Mamura, J. J. Letterio, J. MacGregor, S. C. Patel, S. Khozin, Z. Y. Liu, J. Green, et al. 2002. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109: 1607-1615.